Diagnosis and overdiagnosis of prostate cancer: a personal view by Tam, PC
Title Diagnosis and overdiagnosis of prostate cancer: a personal view
Author(s) Tam, PC
Citation Hong Kong Medical Journal, 2012, v. 18, p. 456-458
Issued Date 2012
URL http://hdl.handle.net/10722/181725
Rights Creative Commons: Attribution 3.0 Hong Kong License
456	 Hong	Kong	Med	J		Vol	18	No	6	#	December	2012	#		www.hkmj.org
The diagnosis of prostate cancer has been changed 
by the introduction of prostate-specific antigen (PSA) 
and transrectal ultrasound (TRUS)–guided spring-
driven biopsies. Most prostate cancers develop in 
the peripheral zone of the prostate, and may then 
be palpated before becoming symptomatic and 
early enough to be curable. However, digital rectal 
examination (DRE) is notoriously inaccurate and its 
relevance in the PSA era may be decreasing. Whereas 
DRE has a roughly 30% positive predictable value 
for prostate cancer, case control studies have found 
that up to 25% of cancer may be found only by such 
examinations and result in a 20% to 30% reduction 
in corresponding cancer mortality.1 Therefore, 
despite its low positive predictive value, DRE is still 
recommended as part of the routine screening 
regimen.
 Transrectal ultrasound is the most common 
approach for imaging the prostate, and has the 
advantage of being able to visualise lesions in the 
prostate that are not palpable. In general, TRUS 
of the prostate is a readily accepted, fairly simple 
procedure that affords excellent visualisation of the 
gland. However, the procedure is hampered by its 
poor performance characteristics with respect to 
sensitivity and specificity for detecting carcinoma, 
and has led most investigators to conclude that TRUS 
as a ‘stand-alone’ screening tool has little usefulness 
for initial diagnostic workup. Nevertheless, TRUS 
is a necessary instrument for accurately spaced 
systematic biopsies. Guided TRUS biopsies, using 
spring-driven instruments, can remove multiple 
(8-12) cores of prostate tissue in a relatively painless, 
highly accurate and safe way. When volume of 
cancer is measured in each biopsy core, along 
with the percentage that is Gleason grade 4 and 5, 
TRUS represents a powerful tool for predicting 
extracapsular cancer and microscopic metastases in 
the pelvic lymph nodes.2
 Prostate cancer tissue elevates serum PSA 
levels of about 3.5 ng/mL per gram of cancer tissue 
while in benign prostatic hyperplasia (BPH) they 
increase only about 0.3 ng/mL per gram of BPH tissue.3 
Since its discovery in 1979 to its clinical application 
in the late 1980s through 1990s, PSA has evolved into 
an invaluable tool for the detection, staging and 
monitoring of men diagnosed with prostate cancer. 
Although PSA is widely accepted as a prostate cancer 
tumour marker, it is organ specific and not disease 
specific. There is an overlap in the serum PSA levels 
among men with cancer and those with benign 
disease. Early studies established the reference range 
of ≤4.0 ng/mL to define normal serum PSA levels. 
Catalona and associates4 detected prostate cancer 
in 22% of a group of men who underwent biopsy at 
PSA levels of 2.6 to 4.0 ng/mL and had non-suspicious 
prostate examinations. The choice of a PSA cut-off 
point above which one would recommend further 
evaluation to rule out prostate cancer is controversial. 
Currently, serum PSA levels as low as 2.6 ng/mL are 
used as a threshold to perform prostate biopsy. 
Although up to 30% of men presenting with an 
elevated PSA may be diagnosed with prostate cancer 
following this invasive procedure, as many as 70% are 
not found to have cancer. 
 Measurable PSA exists either as complexed 
form (cPSA) or as a free form (fPSA). Although 
the majority of serum PSA is found complexed 
to proteins, 5% to 35% exists as fPSA. Men with 
prostate cancer have a greater fraction of serum 
PSA complexed to proteins and a lower percentage 
of total PSA that is free compared with men without 
prostate cancer. Using this important observation 
led to the measurement of the ratio of free to total 
PSA (% fPSA) and has since provided an additional 
degree of specificity for prostate cancer detection.5 
Application of PSA derivatives such as molecular 
derivatives have attempted to improve the specificity, 
but this will undoubtedly impair its sensitivity. For 
the time being it seems sensible to continue using 
cut-off values of PSA. 
 Because of PSA’s low positive predictive value, 
up to 75% of men with levels in the range of the 
2.5-10 ng/mL and/or suspicious DRE findings still have 
negative biopsies. These biopsies must be viewed not 
only from an economic point of view, but also from 
the perspective of the anxiety and discomfort they 
generate, and the severe complications they may give 
rise to. Thus, there is a need for additional tests to 
increase the probability of detecting prostate cancer 
and reducing the number of unnecessary biopsies. In 
this respect, the Prostate CAncer gene (PCA-3) assay, 
a new prostate cancer gene-based marker, has shown 
promising results.
 Expression of PCA-3 protein has been localised 
to prostatic tissue and de Kok and colleagues6 showed 
a 66-fold up-regulation of this protein in cancerous 
as opposed to normal control tissue. Using a real-
time quantitative reverse transcriptase polymerase 
chain reaction assay, it is possible to detect PCA-3 in 
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urine specimens from men with prostate cancer. To 
enhance the sensitivity of such assays, urine samples 
have to be collected after DRE, which conceptually 
will loosen and shed the cells within the prostate and 
therefore enhance the chance of detection. Several 
clinical studies have evaluated the utility of PCA-3 
to serve as a prostate cancer biomarker. However, 
despite supporting evidence for the beneficial 
role of PCA-3 in diagnosing prostate cancer in the 
western population, information regarding its utility 
in the Chinese is scanty. Thus, in this journal issue, 
Ng and associates7 provide some insight on the role 
of PCA-3 in diagnosing prostate cancer in a Chinese 
population.
 Notably, PSA testing continues to be one of the 
most controversial topics in cancer screening. The 
potential benefits include prevention of prostate 
cancer morbidity and mortality, but men may be 
harmed through overdiagnosis and overtreatment. 
Two important studies demonstrated a mortality 
benefit: the European Randomized Study of Screening 
for Prostate Cancer (ERSPC8) and the overlapping 
Göteborg trial.9 The other large randomised 
controlled trial, Prostate, Lung, Colorectal, Ovarian 
(PLCO) cancer screening trial10 showed no mortality 
benefit for organised annual screening compared 
to opportunistic screening. Many explanations 
account for the discrepancy in results between these 
studies, including high rates (52%) of opportunistic 
PSA screening in the control arm of PLCO trial 
and differences in treatment between two arms 
in the ERSPC study. Investigators in the ERSPC trial 
estimated that 37 men would need to be screened 
and treated (NNT) to prevent one prostate cancer 
death after a median 11 years of follow-up; in the 
Göteborg trial,9 the NNT was 12 after 14 years. Based 
on the best available evidence, screening with PSA 
testing is associated with modest improvement in 
mortality. 
 The harms of PSA screening include false-
positive test results in up to 13% of screened men8 
and can be associated with significant psychological 
distress, in addition to the potential adverse effects 
of biopsy (bleeding, urosepsis, and acute urinary 
retention). Many men diagnosed with prostate 
cancer by screening have low-risk disease, which is 
associated with a low risk of prostate cancer–specific 
death after 15 years. Currently available screening 
tests are not able to identify which individual 
requires treatment and which men have disease 
that is truly clinically insignificant. Overdiagnosis 
means either non-progressive or very slow–growing 
cancers are identified, they pose no real threat to 
the patients. The problem is that it can be difficult to 
determine with confidence when a cancer diagnosis 
amounts to overdiagnosis. Attention is now turning 
to the questions of how to limit the harms that result 
from PSA screening, namely, how to mitigate the 
conversion of overdiagnosis into overtreatment. 
 Active surveillance has emerged in recent 
years as an option for initial treatment for low-risk 
disease. In this management strategy, men with 
low-risk prostate cancer are followed closely after 
diagnosis, and treated with curative intent only if 
their disease exhibits more aggressive behaviour. 
This approach differs significantly from watchful 
waiting, in which men, usually older men with 
significant co-morbidities, are offered only palliative 
treatment if they develop symptoms from their 
cancer. Prospective studies of active surveillance 
have entailed only limited follow-up; 30% of the 
men involved had been treated, and enjoyed a 
prostate cancer–specific survival of 97.2% at 10 
years.11 In the public mind, cancer is a lethal disease 
to be destroyed at all cost. This reaction can lead to 
overtreatment, with significant side-effects and costs. 
Patient education is a key solution to the problem of 
overtreatment. 
 Screening for prostate cancer appears to be 
based on the best data from randomised trials to 
reduce cancer mortality. However, reducing over-
treatment in patients diagnosed with insignificant 
disease is critical to the success of screening. Active 
surveillance is a major step forward in addressing 
that concern. Genomics and biomarkers hold the 
promise of more accurate prediction of individual 
tumour behaviour. In 2012, however, these still have 
not achieved widespread application and acceptance.
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